<DOC>
	<DOCNO>NCT00111761</DOCNO>
	<brief_summary>The purpose study determine panitumumab , combination irinotecan , leucovorin , 5-fluorouracil ( 5-FU ) safe efficacious patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Evaluating Panitumumab ( ABX-EGF ) Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Indication Metastatic Colorectal Cancer Primary Objective To assess safety ABX-EGF combination FOLFIRI regimen subject metastatic colorectal cancer . ( The primary objective original protocol assess progression free survival treatment ABX-EGF combination Saltz regimen subject metastatic colorectal cancer ) . Secondary Objective ( ) To assess clinical efficacy ABX-EGF combination FOLFIRI regimen subject metastatic colorectal cancer . ( Secondary objective original protocol ass safety additional measure clinical efficacy ABX-EGF combination Saltz regimen subject metastatic colorectal cancer ) . To assess pharmacokinetics ( PK ) ABX-EGF combination FOLFIRI regimen subject metastatic colorectal cancer . ( Secondary objective original protocol assess PK ABX-EGF combination Saltz regimen , PK irinotecan ( IR ) active metabolite SN-38 IR give combination ABX-EGF , leucovorin ( LV ) , 5-fluorouracil ( 5-FU ) subject metastatic colorectal cancer )</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Able comprehend sign Institutional Review Board ( IRB ) approve informed consent form Pathologic diagnosis colorectal cancer Metastatic colorectal adenocarcinoma If history adjuvant chemotherapy colorectal cancer , must free disease great equal 1 year completion adjuvant chemotherapy Unidimensionally measurable disease Paraffinembedded tumor tissue available immunohistochemistry study epidermal growth factor receptor ( EGFr ) expression ( archived tissue acceptable ) Tumor overexpressing EGFr immunohistochemistry ( stain must sum 1+ , 2+ 3+ great equal 10 % evaluated tumor cell ; stain evaluation conduct central laboratory ) Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 Adequate hematologic , renal , hepatic function Female ( childbearing potential , postmenopausal le 6 month , surgically sterilize , abstinent ) consenting use adequate contraceptive precaution course study 6 month last ABXEGF infusion Female breastfeeding pregnant Any kind disorder compromise ability patient give write informed consent and/or comply study procedure History chronic medical psychiatric condition laboratory abnormality , opinion investigator , may increase risk associate study participation study drug administration may interfere compliance interpretation study result Untreated brain metastasis Therapy colorectal cancer surgery 5FUbased adjuvant therapy Prior treatment metastatic colorectal cancer Prior irinotecan Prior concurrent radiation therapy colorectal cancer , include prior adjuvant radiation therapy pelvis Known allergy irinotecan , 5fluorouracil , leucovorin Known Gilbert 's disease Known dihydropyrimidine dehydrogenase ( DPD ) deficiency Prior EGFrtargeting agent Use investigational therapy use adjuvant intent within 30 day first ABXEGF infusion If prior history cancer colorectal carcinoma , basal cell carcinoma , cervical carcinoma situ , treatment active disease within 5 year Active inflammatory bowel disease bowel disease ( colorectal carcinoma ) cause chronic diarrhea ( define great 4 stool per day ) Partial complete bowel obstruction , know chronic malabsorption , total colectomy , major abdominal surgery might result substantial alteration transit absorption oral medication Ascites pleural effusion require therapeutic paracentesis thoracentesis ; subject small , stable , asymptomatic pleural effusion ascites may enrol ; subject render asymptomatic successful sclerosis effusion may enrol . Active interstitial pneumonia interstitial fibrosis Left ventricular ejection fraction ( LVEF ) less 45 % , measure multiplegated acquisition ( MUGA ) scan Myocardial infarction within 1 year first ABXEGF infusion Any follow within 6 month first study drug dose : Unstable angina ; Symptomatic congestive heart failure ; Serious uncontrolled cardiac arrhythmia ; Cerebrovascular accident transient ischemic attack ; Pulmonary embolism ; Deep vein thrombosis ; Other significant thromboembolic event . Subject know human immunodeficiency virus ( HIV ) positive History chronic medical psychiatric condition laboratory abnormality , opinion Investigator , may increase risk associate study participation study drug administration may interfere patient compliance interpretation study result Unwilling unable comply study requirement Known allergy ingredient study drug Staphylococcus protein A</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Immunex</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>ABX-EGF</keyword>
	<keyword>Abgenix</keyword>
</DOC>